Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos

An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 34) CDR3: X2-5DY (SEQ ID NO: 35) wherein X1 is N or Q, and X2-5 is YWLF, GWTF or AWTM, and wherein if X2-5 is GWTF or AWTM, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer. (Traducción automática con Google Translate, sin valor legal) An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 34) CDR3: X2-5DY (SEQ ID NO: 35) wherein X1 is N or Q, and X2-5 is YWLF, GWTF or AWTM, and wherein if X2-5 is GWTF or AWTM, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.